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Abstract
Insulin-like growth factor 2 (IGF2) overexpression is an important molecular marker of adrenocortical carcinoma (ACC), which
is a rare but devastating endocrine cancer. It is not clear whether IGF2 overexpression modifies the biology and growth of
this cancer, thus more studies are required before IGF2 can be considered as a major therapeutic target. We compared the
phenotypical, clinical, biological, and molecular characteristics of ACC with or without the overexpression of IGF2, to address
these issues. We also carried out a similar analysis in an ACC cell line (H295R) in which IGF2 expression was knocked down
with si- or shRNA. We found no significant differences in the clinical, biological and molecular (transcriptomic) traits
between IGF2-high and IGF2-low ACC. The absence of IGF2 overexpression had little influence on the activation of tyrosine
kinase pathways both in tumors and in H295 cells that express low levels of IGF2. In IGF2-low tumors, other growth factors
(FGF9, PDGFA) are more expressed than in IGF2-high tumors, suggesting that they play a compensatory role in tumor
progression. In addition, IGF2 knock-down in H295R cells substantially impaired growth (.50% inhibition), blocked cells in
G1 phase, and promoted apoptosis (.2-fold). Finally, analysis of the 11p15 locus showed a paternal uniparental disomy in
both IGF2-high and IGF2-low tumors, but low IGF2 expression could be explained in most IGF2-low ACC by an additional
epigenetic modification at the 11p15 locus. Altogether, these observations confirm the active role of IGF2 in adrenocortical
tumor growth, but also suggest that other growth promoting pathways may be involved in a subset of ACC with low IGF2
expression, which creates opportunities for the use of other targeted therapies.
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Introduction
Insulin-like growth factor 2 (IGF2) is a polypeptide hormone
with high homology to proinsulin and IGF1. IGF2 is an autocrine,
paracrine and endocrine factor which binds with high affinity to
membrane-bound tyrosine kinase receptors [1]. Insulin and IGF1
are specific for their cognate receptors, whereas IGF2 has similar
affinities for the IGF1 receptor (IGF1R) and the short isoform of
the insulin receptor (INSR). The binding of IGF2 to IGF1R and
INSR activates the PI3kinase/Akt and MAP kinase pathways and
regulates cell division and survival [2]. In addition, IGF2 binds to
several specific IGF binding proteins (IGFBP) and the IGF2/
mannose6P receptor, which all regulate the bioavailability of IGF2
[3].
IGF2 exerts its proliferative effects in many tissues and its
physiological action has been demonstrated primarily during fetal
growth [4]. Accumulating data indicate that IGF2 is produced in
large amounts by subsets of embryonic tumors, including Wilms
tumors, rhabdomyosarcoma [5], hepatoblastoma and neuroblas-
toma [6]. Subsets of adult cancers also overexpress IGF2,
including 20% of hepatocarcinoma [7], 40% of colon carcinoma,
90% of liposarcoma [8], and also adrenocortical carcinoma [9].
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The production of IGF2 in adult adrenocortical cancer (ACC)
and its role in adrenocortical malignant tumorigenesis has been
extensively investigated [10]. Unlike adrenocortical adenoma
(ACA) which is frequent (2 to 3% of the general population) and
is often found incidentally, ACC is extremely rare and has a very
poor prognosis [11]. This cancer is revealed either by its
tumorigenic progression (compression, metastasis) or more often,
by the symptoms of the over-production of steroids (cortisol and
androgens, but also estrogens and aldosterone) [12]. Many studies
have attempted to identify markers for the diagnosis and prognosis
of these tumors. Among these markers, the overexpression of
IGF2 has been recognized for over 20 years [9]. IGF2
overexpression has been extensively analyzed [13-15]. Both
IGF2 mRNA (10 to 20 fold higher than normal adrenal gland
or ACA) and protein (8 to 80 fold higher than normal adrenal
gland or ACA) are overexpressed in 90% of ACC, with a strong
correlation between mRNA and protein abundance [13]. IGF2
overproduction is the consequence of paternal uniparental disomy
(pUPD) of the IGF2 locus at the 11p15.5 region or a loss of
imprinting (LOI) of the maternal allele [14,15]. The ACC cell line
H295R recapitulates the IGF2 abnormalities of most ACC, with a
high abundance of IGF2 mRNA and protein [16], a low
abundance of H19 and CDKN1C suggesting 11p15 pUPD, and
TP53 mutation [17]. This cell line is therefore a good model to
study the role of IGF2 in the development of these tumors. The
proliferation of this cell line is inhibited by anti-IGF2 [16] and
anti-IGF1R antibodies [18], and by specific inhibitors of IGF1R
[19]. Several pangenomic transcriptome microarray analyses,
including ours, have shown recently that IGF2 is the most
differentially expressed gene between malignant and benign
adrenocortical tumors [20–23]. Conversely, the overexpression
of IGF2 specifically in the adrenal cortex of transgenic mice has no
major tumorigenic effect [24,25]. However, several questions
remain unsolved: when and how is IGF2 important in ACC
development? Are ACC that do not overproduce IGF2 pheno-
typically different from those overproducing this growth factor? Is
this growth factor and its signaling pathway a good therapeutic
target in ACC?
In the present study, we compared the phenotypic traits and
transcriptome of ACC tumors and cells with or without IGF2
overexpression. Our findings shed new light on the role of IGF2 in
ACC tumor progression.
Material and Methods
Patients
Samples of sporadic adrenal tumors were obtained from 140
patients mostly followed up at Cochin hospital (Paris, France)
between 1993 and 2008 and within the Comete network. The
median follow-up period was 51 months. Among these tumors, 87
were diagnosed as ACA (Weiss ,3), and 53 as ACC (Weiss $ 3)
according to criteria described by Weiss et al. [26]. A
transcriptome analysis was reported previously for 47 adenoma
and 29 ACC; 23 overexpress IGF2 and six do not [21]. IGF2
expression was measured by quantitative RT-PCR, as previously
described [21], identifying two subgroups of ACC with or without
overexpression of IGF2: ACC IGF2-high, n= 43 (81%), and ACC
IGF2-low, n= 10 (19%). The clinical, histopathological, and
biological features of these tumors are summarized in Table 1.
The Ki67 value was determined by immunohistochemistry. The
LOH status of 17p13 was inferred from the study of microsatellite
markers [27]. Molecular markers of risk of recurrence and poor
prognosis were described previously from quantitative RT-PCR
measurements of DLGAP5 (DLG7), PINK1 and BUB1B
expression [21]. Informed signed consent for the analysis of the
tumor and for access to the data collected was obtained from all
Table 1. Clinical, histopathological, and molecular features of adrenal adenoma, IGF2-low carcinoma, and IGF2-high carcinoma.
Adenomas
(n =87)
CS IGF2-low
(n=10)
CS IGF2-high
(n =43)
p-value (CS IGF2-low vs CS IGF2-
high)
Sex (Men/Women) 8/79 2/8 10/33 1a
Age at diagnosis (median (range), year) 48 (22–76) 57.5 (26–81) 45 (15–79) 0.17b
Weight (median (range), g) 16 (5–240) 134.5 (40–551) 249 (50–2700) 0.09 b
Size (median (range), cm) 3.5 (2–10) 9 (4–16) 11 (5–24) 0.31 b
Weiss score (median (range)) 0 (0–2) 6 (3–9) 6 (3–8) 0.7 b
ENSAT score (median (range)) 1 (1–2) 2 (1–4) 2 (1–4) 0.52 b
Secretion (yes/no) 53/34 10/0 34/9 0.18 a
Ki67 (median (range), positive cells/1000) 0 (0–18) 14 (0–118) 8.5 (0–269) 0.85 b
Metastatic (yes/no) 0/87 5/5 22/20 1 a
Treatment (surgery/surgery + mitotane) 83/4 4/5 14/25 0.7 a
17p13 LOH (yes/no) 0/22 7/3 26/5 0.38 a
DLGAP5 (DLG7)-PINK1 elevated risk of recurrence (yes/no) 0/87 8/2 26/15 0.46 a
BUB1B-PINK1 poor prognosis (yes/no) 0/87 7/3 24/18 0.72 a
TP53 mutation (yes/no) NA 3/4 5/33 0.09 a *
Abnormal TP53 IHC (yes/no) NA 4/4 8/27 0.19 a
CTNNB1 mutation (yes/no) NA 2/6 6/32 0.61 a
Abnormal CTNNB1 IHC (yes/no) NA 4/4 8/27 0.19 a
These various characteristics were determined as detailed in Material and Methods. P-values were calculated with the Fisher’s exact test (a) or Wilcoxon test (b) and show
no significant differences between IGF2-high and IGF2-low ACC. When numbers do not add up to 10 for IGF2-low and 43 for IGF2-high, this indicates that data are not
available for all patients.
doi:10.1371/journal.pone.0103744.t001
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the patients, and the study was approved by the institutional
review board of the Cochin Hospital.
Cellular models of IGF2 knock-down in H295R cells
H295R cells, which are derived from an adrenal carcinoma
overexpressing IGF2, were ordered from ATCC, and cultured as
described previously [28].
For the transient knock-down of IGF2, siRNA duplexes against
IGF2 (forward sequence 59UCGUUGAGGAGUGCUGUU-
UdTdT39) and a control siRNA with no target in the human
genome (forward sequence 59GGCAUAGAUGUAGCUGUA-
AdTdT39) were designed and obtained from Eurogentec. For the
efficient knock-down of IGF2, 3.105 cells were transfected twice
with 50 pmol siRNA, at day 1 and 2 after cell plating, with the
Effectene transfection reagent (Qiagen) according to manufactur-
er’s instructions.
For the stable knock-down of IGF2, H295R cells stably
expressing a Tet repressor (H295R/TR clone) were kindly
provided by Dr Lalli [29]. A linker 59GATCCCCATCGTT-
GAGGAGTGCTGTTTCAAGAGAACAGCACTCCTCAACG-
ATGTTTTTA39 39GGGTAGCAACTCCTCACGACAAAGT-
TCTCTTGTCGTGAGGAGTTGCTACAAAAATTCGA59 was
subcloned into the BglII-HindIII sites of the pSUPERIOR.puro
vector (Oligoengine) to generate clones expressing a doxycycline-
inducible IGF2 shRNA. H295R/TR cells were transfected further
with the pSUPERIOR.puro/shRNA IGF2 plasmid and clones were
selected with puromycin (5 mg/mL). A dose-response curve showed
that 10 ng/mL of doxycycline was sufficient for the maximal knock-
down of IGF2 by the shRNA (data not shown).
Doxycycline does not modify IGF2 expression in H295R/TR
cells or control clones transfected with an empty pSUPERIOR.-
puro plasmid (data not shown).
Cell Proliferation, apoptosis and cell cycle assays
Cell proliferation was measured with the CellTiter 96 wells
Non-Radioactive Cell Proliferation Assay (Promega), according to
manufacturer’s instructions (quick protocol). Cells (8000/well)
were plated on 96-well plates and the first measurement (D0) was
made 3 days later. Optical absorbance was measured at 570 nm in
a microplate reader.
Apoptosis was analyzed by staining cells with Annexin V with
the Annexin-V-FLUOS Staining Kit (Roche), according to
manufacturer’s instructions. Cells were analyzed by flow cytom-
etry with a Cytomics TM FC500 (Beckman Coulter), and data
were processed with Cytomics RXP software.
Spontaneous apoptosis was studied in stable clones after 10 days
of IGF2 knock-down induced by doxycycline treatment.
TNF-alpha-induced apoptosis was analyzed in H295R cells
after transient IGF2 knock-down by siRNA for 48 h, followed by a
48 h treatment with 20 ng/mL TNF-alpha (eBioscience).
For cell cycle analysis, cells were seeded in 6-well plates. At time
of analysis, cells were trypsinized, rinsed with PBS and fixed in
500 mL of 70% ethanol. They were then centrifuged, rinsed in
PBS, and suspended in 50 mg/mL of propidium iodide + 100 mg/
mL RNase A. Analysis by flow cytometry was performed with a
Cytomics TM FC500 (Beckman Coulter), and data were processed
with Cytomics RXP software.
Quantitative RT-PCR
Reverse transcription of RNA from tumors. IGF2-high
(23 samples) and IGF2-low (10 samples) ACC were studied by
quantitative RT-PCR. Total RNA was extracted from tumors as
described previously [21] and reverse transcribed (1.5 mg in
100 ml) with the High Capacity cDNA Reverse Transcription kit
(Applied Biosystems).
Reverse transcription of RNA from cell lines. Total RNA
was extracted from cell lines with the RNeasy Mini kit and RNase-
free DNase Set (Qiagen) according to the manufacturer’s
instructions. Purified RNA was reverse transcribed (500 ng in
20 ml) with Superscript II RNA polymerase kit (Invitrogen).
RT-PCR. The expression of target genes was analyzed by
quantitative PCR with a LightCycler Fast Start SYBR Green kit
(Roche Diagnostics) according to the manufacturer’s instructions.
Briefly, 2.5 ml of 10-fold diluted reverse transcription product was
used with 500 nM of each primer in a 10 ml reaction. Optimal
annealing temperature, PCR efficiency, and PCR specificity
(dissociation curve to verify amplification of one product) were
determined with a four-point dilution curve. Conditions are
described for all target genes in Table S1.
Analyses for tumors. Relative quantification of target
cDNA was determined by calculating the difference in cross-
threshold (CT) values after normalization to 18SRNA5 signals
(DDCT method), taking a normal adrenal sample as a reference. In
our previous study, 18S mRNA was validated as the best reference
gene, with perfect correlation between microarray and qPCR
results [21]. Similar results were obtained using GAPDH as
reference gene (data not shown). Each sample was analyzed in
duplicate.
Analyses for cell lines. IGF2 and PP1A mRNA levels were
quantified using dilution curves included in the experiments. No
variation of PP1A level was observed after siRNA or doxyxycline
treatment, showing that it is a reliable reference gene for these
experiments. Ratio between IGF2 and PP1A levels was fixed to
one when IGF2 was not knocked-down (control siRNA or no
doxycycline treatment).
Western blot
IGF2-high and IGF2-low ACC (10 samples each) were studied
by western blot. Whole cell protein lysates were obtained from
tumors by extraction with RIPA lysis buffer (50 mM Tris–HCl,
pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.1% v/v Nonidet P-40
(NP40), 1 mM dithiothreitol (DTT)) with inhibitors of proteases
(Complete Protease Inhibitor Cocktail Tablets, Roche) and
phosphatases (PhosSTOP Phosphatase Inhibitor Cocktail Tablets,
Roche). Western blotting was done according to standard
procedures [30] with chemiluminescence and films (Amersham
hyperfilm ECL, GE healthcare). Antibodies and conditions are
described in Table S2.
Western blot bands were quantified with the GeneTools software
(http://www.syngene.com/genetools-software-download).
Transcriptomic analyses
Transcriptomic analyses of adrenocortical tumors (47 ACA, 23
IGF2-high ACC and six IGF2-low ACC) were reported previously
[21]. All data are available at the ArrayExpress Web site (http://
www.ebi.ac.uk/arrayexpress, experiment E-TABM-311) and were
confirmed by quantitative RT-PCR of more than 100 genes.
Transcriptomic analyses of three different H295R clones, with
or without IGF2 knock-down for 2 or 10 days, was carried with
Human gene 1.0 ST array (Affymetrix). Moreover, the same
analysis was done after a 5 day transient inhibition of IGF2 by
siRNA in H295R cells, in normal (2% of Ultroser G serum, Pall
Biosepra) or depleted medium (without UltroserG, depletion from
one day before siRNA transfection to the end of the experiment).
Total RNA was extracted from cell lines with the RNeasy Mini
kit and RNase-free DNase Set (Qiagen) according to the
manufacturer’s instructions, and RNA quality was evaluated by
IGF2 in Adrenocortical Carcinoma Growth
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Bioanalyzer (Agilent). All raw data for cell line microarray
experiments are available upon request.
11p15 locus Methylation studies
The methylation of the telomeric and centromeric 11p15
Imprinting Center Regions, termed ICR1 and ICR2, respectively,
were analyzed by allele-specific methylated multiplex real time
quantitative PCR (ASMM RTQ-PCR) as described previously
[31,32]. These analyses were performed on 15 IGF2-high and
nine IGF2-low tumors for which tumor DNA was available.
Sequencing
The three coding exons and adjacent intronic regions of IGF2
gene were amplified by PCR with the primers indicated in the
lower part of table S1 and the amplicons were sequenced by the
Sanger method (Sequencer Applied Biosystem 3130 XL ABI
Prism 16 capillaries and Big Dye Terminator V1 Kit).
Figure 1. IGF2 mRNA levels and prognoses of IGF2-high and IGF2-low ACC. A: Boxplot showing IGF2 mRNA levels in normal adrenals
(n = 4), ACA (n = 87), IGF2-low ACC (n= 10), and IGF2-high ACC (n = 43). IGF2-low ACC have similar levels of IGF2 to normal adrenals and ACAs. There is
a minimal 6.5 fold difference between IGF2-high and IGF2-low ACC and there is a 200-fold difference between their median expressions. B: Kaplan-
Meier survival curves showing overall (left) and disease-free (right) survival of patients with IGF2-low ACC (n= 10) or IGF2-high ACC (n = 43). P-values
from a Cox regression analysis between IGF2-high and IGF2-low ACC are indicated, showing that there is no difference between the two groups.
doi:10.1371/journal.pone.0103744.g001
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Statistical analyses
Survival Kaplan-Meier curves, Fisher and Wilcoxon statistical
tests were carried out with R software.
Genes differentially expressed between IGF2-high and IGF2-
low ACCs in the transcriptomic study were determined with the
limma t-test (R package).
Genes that showed significantly modified expression following
IGF2 knock-down in cellular models were defined with a paired t-
test on the eight independent cellular experiments (three clones
analyzed at 2 and 10 days after IGF2 knock-down, and two siRNA
experiments with 5 days of IGF2 knock-down in normal or
depleted medium, see above).
Pathways analysis was performed as follows: (i) Pathways were
obtained from KEGG, Gene Ontology, Biocarta, MSigDB and
Stanford Microarray Database websites. (ii) Gene lists tested for
enrichment were based on the top 500, 250 and 100 probe sets
sorted by p-value (for a given comparison – paired t-test in cell
models and limma t-tests in tumors). These lists of up-regulated or
down-regulated genes were analyzed for pathway enrichment. (iii)
Hypergeometric tests were used to measure the association
between gene lists and pathways.
Results
Tumor and Cell models
We studied phenotypical differences between adrenocortical
carcinoma cells with or without the overexpression of IGF2 in two
different models:
N Adrenocortical carcinoma samples with or without the
overexpression of IGF2. The cohort included 53 patients
who underwent surgery between 1993 and 2008 for an ACC.
This cohort was divided into two groups on the basis of IGF2
mRNA abundance: the tumor was considered as IGF2-high
when its expression was at least 25 higher than normal
adrenals. IGF2-low ACC had levels similar to normal adrenals
(0.025 to 4.07 fold) (Figure 1A).
N Adrenocortical carcinoma cells (H295R) express large amounts
of IGF2. We knocked-down IGF2 expression in these cells
with either siRNA (transient knock-down) or with shRNA,
which enables an inducible and stable knock-down of IGF2.
IGF2 expression was 84% lower than control values at days 2
and 3 after transient transfection (p,0.05) (Figure S1A) and
remained significantly low (74% lower than control) at day 5 in
three independent experiments. In four independent stably
transfected clones treated with doxycycline, the abundance of
IGF2 was significantly lower than in untreated clones (40 to
74% lower at day 2 and 64 to 89% lower at day 10) (Figure
S1B).
IGF2-high and IGF2-low adrenocortical carcinoma have
similar clinical, histopathological and molecular markers
and features
The first goal of this study was to compare the phenotypic traits
of ACC that overexpress IGF2 with those that do not. We
analyzed first the clinical differences between IGF2-high and
IGF2-low ACC. As indicated in Table 1, sex ratio, age at
diagnosis and size and weight of tumors were not strikingly
different between the two types of tumors. In addition, prolifer-
ation and invasiveness were not significantly different as assessed
by the Weiss score, Ki67 index and ENSAT stage [33]. The
occurrence of metastasis was also similar. Patients received similar
treatment regimens (surgery alone or surgery + mitotane) and
molecular markers of carcinoma diagnosis and prognosis were not
different in the two groups. These observations were supported by
the comparison of the overall and event-free survival for IGF2-
high carcinoma and IGF2-low carcinoma (Figure 1B). Again, the
two groups of ACC presented similar survival (Logrank p= 0.57
and p= 0.99 for overall and event-free survival, respectively),
which was significantly different from the survival of patients with
ACA (p,1.10-14 for both overall and event-free survival, data not
shown). In the previously described unsupervised clustering of the
ACC transcriptome, which identified two clusters with very
different prognoses (Figure 1A of reference [21]), IGF2-low ACC
did not cluster apart from IGF2-high ACC (data not shown).
Altogether, these data indicate that there is no major phenotypic
difference between the IGF2-low and IGF2-high carcinoma in
terms of clinical, histological and molecular markers. IGF2 status
is clearly correlated with malignancy [14], but it is not a prognostic
marker in carcinoma.
We used the same transcriptomic data [21] to identify genes
differentially expressed between IGF2-high and IGF2-low ACC
and we searched for pathways enriched in differentially expressed
genes (Table S3-ACC-pathways). Gene expression, transcription,
cell cycle regulation (especially the G1/S transition), and p53 were
among the pathways enriched in genes highly expressed in IGF2-
high tumors. Multidrug resistance factors, Jak-STAT, and
response to oxidative stress were among the pathways enriched
in genes highly expressed in IGF2-low tumors.
We carried out the same pathway enrichment analysis on the
transcriptomic data of H295 cells with or without the knock-down
of IGF2 (Table S4). The expression of genes involved in the G1/S
transition of cell cycle, apoptosis, insulin and p53 signaling was
significantly impaired by IGF2 knock-down. Genes up or down-
regulated both in tumor and cellular models, which are potential
targets of IGF2, are listed in Table S5.
Expression and activity of IGF signaling pathways in IGF2-
high and IGF2-low tumors and cells
Data from microarray experiments analyzing the transcriptome
of adrenocortical tumors [21] suggest few differences in the
expression of IGF pathway members between IGF2-low and
IGF2-high carcinoma. These results were obtained with a limited
number of IGF2-low ACC (n= 6); therefore, we sought to validate
these findings. We assessed the expression of 18 partners
associated with the IGF signaling pathway, including receptors,
IGFBPs, Akt, PI3K and Erk isoforms, by quantitative RT-PCR in
10 IGF2-low and the 23 IGF2-high carcinoma. In addition, we
analyzed the protein abundance of receptors, Akt and Erk
isoforms by western blotting in 10 tumors of each group. Most
of the 18 studied genes were not differentially expressed between
IGF2-high and IGF2-low ACC, and the few significant differences
were modest (Figure 2A). There was a strong correlation between
transcriptomic and quantitative RT-PCR data, and we confirmed
several of these results by western blotting. The most important
findings of this study are presented in Figure 2 and the complete
data set is accessible in Table S6. Notably, the expression of the
short isoform of INSR was not different between the two groups
(Table S6). Significant differences included a 2 to 3-fold higher
abundance of Erk2 protein and mRNA, total Erk (Erk1 + Erk2)
proteins, IGFBP5 and PI3KCA mRNAs in the IGF2-low tumors
(Figure 2B) and a 3-fold higher abundance of mRNAs encoding
IGFBP3 in the IGF2-high tumors (Figure 2C). We confirmed
these findings in the cellular model; the efficient knock-down of
IGF2 did not modify the expression of the factors assessed by
transcriptomic analysis (Table S3-cellular models-genes) and by
western blotting (Figure S2 B, C, E, G). These results indicate that
IGF2 in Adrenocortical Carcinoma Growth
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overexpression of IGF2 has no major effect on the expression of
the members of its signaling pathway.
We then examined whether the activation of the IGF, Erk, and
Akt pathways was different between IGF2-high and IGF2-low
ACC. We assessed the abundance of the phosphorylated forms of
these proteins in 10 tumors from each group by western blotting.
The phosphorylation of IGF1 and insulin receptors was higher in
IGF2-high carcinoma than in IGF2-low carcinoma, but there was
no difference in the phosphorylation status of Akt and Erk1/2
when normalizing to total Akt or Erk1/2 respectively (Figure 3) or
actin (data not shown). These results are very surprising because
the higher expression of IGF2 in IGF2-high ACC should result in
a robust stimulation of these two pathways. We cannot exclude
that the residual expression of IGF2 in IGF2-low ACC may
stimulate these pathways, although this is unlikely. Another
explanation is that other growth factors or their receptors are
more expressed in IGF2-low tumors than in IGF2-high tumors.
Indeed, our comparison of the transcriptome between IGF2-high
and IGF2-low ACC identified some growth factors (FGF9,
PDGFA, TNFSF10, and TNFSF4) that were 2-fold more
expressed in IGF2-low ACC than in IGF2-high ACC (underlined
in yellow in Table S3_ACC_genes). Differential expressions of
FGF9 and PDGFA were confirmed by quantitative RT-PCR
(Table S6).
We carried out similar experiments in H295R clones. INSR/
IGF1R phosphorylation was unaffected by IGF2 knock-down
(Figure S2A). Moreover, Erk and Akt pathways (Figure S2D-G)
were not inhibited. Surprisingly, we observed a significant
stimulation of Erk1/2 phosphorylation after 7 and 10 days of
IGF2 knock-down. These results prompted us to analyze the
tumorigenic role of IGF2 in adrenocortical cells.
IGF2 knock-down in H295R cells impairs proliferation,
leads to a G1 arrest and promotes apoptosis
The stable knock-down of IGF2 dramatically impaired cell
proliferation in an MTT assay (Figure 4A), whereas cell prolifer-
ation was not affected in a doxycycline-treated control clone
(Figure 4B). This effect was apparent as soon as 4 days after the
initiation of doxycycline treatment, and was maximal at D14. At
this time point, the number of cells of clone 4 treated with
doxycycline was 2.4 times lower than the number of cells not
treated with doxycycline (67666.7 without Dox versus 288613
with Dox, p,0.001). We observed a similar impairment of cell
proliferation in the other three clones, ranging from 1.7 to 2.3-fold
reduction of proliferation at D14 (data not shown). These data
indicate an important role for IGF2 in the growth of the
adrenocortical tumor cell line H295R.
We then investigated the consequences of IGF2 knock-down on
the cell cycle. A significant proportion of cells were arrested in G1
Figure 2. Quantitative expression of IGF signaling pathway members. Boxplots showing the mRNA (quantitative RT-PCR) and/or protein
(western blot) levels of several IGF2 pathway members in IGF2-high (n = 23 for RT-PCR and n= 10 for western blot) and IGF2-low (n= 10) ACC. Y-axis
for mRNA: result of the DDCT method (2
-DDCT value), with RNA18S5 as a reference gene. Y-axis for protein: results of the quantification of the western
blot bands, normalized to actin. Wilcoxon test results (*p,0.05; **p,0.01; ***p,0.00; NS =not significant) are indicated for each mRNA or protein
studied. A: IGF2 and its receptors. B: Erk and Akt. C: other IGF2 pathway members with significantly different expression between IGF2-high and IGF2-
low ACC.
doi:10.1371/journal.pone.0103744.g002
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after 7 days of doxycycline treatment (Figure 4C). For clone 1, the
percentage of cells in G1 was 77.3%63.1 with doxycycline versus
63.5%62.4 without (p,0.05). In parallel, the number of cells in S
phase was 1.95-fold lower in doxycycline-treated cells (8.2%60.7
versus 15.9%63.6). We confirmed these findings in the other three
clones; in doxycycline-treated cells the percentage of cells in G1
was 5 to 14% higher and the percentage of cells in S phase was 11
to 28% lower than in control conditions (data not shown). The cell
cycle was unaffected in a control clone treated with doxycycline
(Figure 4D). Microarray experiments showed down-regulation of
two cyclin-dependant kinases (CDK2 and CDK8) and one of their
positive regulators (CKS1B) (Table S4). These data support a role
for IGF2 in the G1/S transition in adrenocortical cell line H295R.
We also studied the effect of IGF2 knock-down on apoptosis by
FACS (Figure 4E). We analyzed spontaneous apoptosis in stable
clones after 10 days of doxycycline treatment to induce IGF2
knock-down. Both early and late apoptosis were significantly
higher in cells expressing IGF2 shRNA than in control cells
(Figure 4F). For clone 4, the percentage of early apoptotic cells was
20.8%62.4 with doxycycline and was 8.4%61.3 without doxy-
cycline (2.5 fold, p,0.001). The percentage of late apoptotic cells
was 5.5%60.9 with doxycycline and was 4.4%60.7 without
doxycycline (1.3 fold, p,0.001). We confirmed this high rate of
apoptosis in the other three clones; the number of apoptotic cells
was 1.8 to 1.9 fold higher in doxycycline-treated cells than in
control cells (data not shown). Apoptosis was unaffected in a
control clone treated with doxycycline (Figure 4G).
We also transfected H295R with siRNA against IGF2 and
induced apoptosis in these cells by TNF-alpha 48 h after
transfection (Figure 4H). These transient knock-down experiments
confirmed the effect of IGF2 knock-down on apoptosis and
demonstrate further the anti-apoptotic role of IGF2 in the
adrenocortical tumor cell line H295R.
Transcriptome analysis shows an increase in PMAIP1 and
BCL2L11 expression following IGF2 knock-down suggesting the
involvement of the intrinsic apoptotic pathway. Two apoptosis
inhibitors (CDKN1A and RNF7) are also down-regulated (Table
S4).
11p15 methylation profiles differ between IGF2-high and
IGF2-low ACC
Finally, we investigated for the possibility of an additional
genetic or epigenetic event at the 11p15 locus, which can explain
the low IGF2 expression in the IGF2-low ACC.
We first looked for genetic alterations in the IGF2 gene by
direct sequencing of the 3 coding exons in six IGF2-low ACC for
Figure 3. IGF signaling pathway activation in IGF2-high and IGF2-low ACC. The activation of Erk (A), Akt (B), and IGF1R/INSR receptors (C)
was analyzed by western blotting with antibodies directed against the phosphorylated form of these proteins, in IGF2-high (n = 10) and IGF2-low
(n = 10) ACC. Boxplots show the quantification of the results of western blots. Y-axis: results of the quantification of the western blot bands
normalized to total Erk, Akt or actin. Wilcoxon test results (*p,0.05; NS =not significant) are indicated. The phosphorylation of the receptors is higher
in IGF2-high than in IGF2-low ACC, whereas the activation of Erk and Akt downstream pathways is similar.
doi:10.1371/journal.pone.0103744.g003
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Figure 4. Consequences of IGF2 knock-down on cellular growth, apoptosis, and the cell cycle in H295R cells. A, B: Consequences of
long-term knock-down of IGF2 on H295R cell growth as assessed by a MTT proliferation test. A: Doxycycline treatment leads to IGF2 knock-down and
to a significant impairment of cellular proliferation in a clone with integrated IGF2 shRNA. Results are presented for clone 4, which showed the most
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which DNA was available. No deleterious point mutation was
detected in the six samples (data not shown).
We next analyzed the methylation of the 11p15 locus. Briefly,
two Imprinting Center Regions (ICR1 and ICR2) are either
methylated or unmethylated in the 11p15 locus. Methylation of
ICR1 controls the expression of the IGF2/H19 genes and its
methylation prevents the binding of the CTCF protein to DNA,
which acts as an insulator between the two genes (Figure 5A).
Therefore, on the paternal allele where ICR1 is methylated, IGF2
is expressed and H19 is not. ICR1 is not methylated on the
maternal allele, thus H19 is expressed and IGF2 is not. Similarly,
ICR2 is methylated on the maternal allele resulting in the
expression of CDKN1C and KCNQ1 but not KCNQ10T1,
whereas ICR2 is not methylated on the paternal allele resulting
in the expression of KCNQ10T1 but not CDKN1C and KCNQ1.
The mechanism of IGF2 expression in adrenocortical tumors has
been extensively analyzed, and it is now clear that this
overexpression is due, at least in part, to paternal uniparental
disomy (pUPD) at the 11p15 locus [14,34]. This pUPD results in
an overexpression of IGF2, but also of KCNQ10T1, whereas the
expression of H19, CDKN1C and KCNQ1 is impaired. In the
present cohort, UPD was characterized previously in 20 IGF2-
high and five IGF2-low ACC by Southern blotting [15]. Of these
samples, 90% of IGF2-high ACC showed pUPD and all IGF2-low
ACC showed the same alteration. We looked at the expression of
the five imprinted genes in the previous transcriptomic study [21]
to confirm these results. As shown in Figure 6 A and B, the
expression pattern of these five genes is compatible with pUPD in
IGF2-high tumors. In IGF2-low tumors, the expression of
CDKN1C, KCNQ1 and KCNQ1OT1 is indicative of the expected
demethylation of ICR2; however, the low expression of IGF2 and
the moderate expression of H19 suggest an unexpected impair-
ment to methylation at ICR1, at least in some tumors.
We confirmed this hypothesis by the analysis of methylation at
ICR1 and ICR2 in 15 IGF2-high and nine IGF2-low tumors
(Figure 5B). This analysis showed that 80% of IGF2-high tumors
had a methylation profile compatible with pUPD, whereas only
30% of IGF2-low tumors had such a pattern. Six of the nine IGF2-
low tumors had low levels of methylation at ICR1, in accordance
with the absence of IGF2 expression. Therefore, these observa-
tions suggest that differences in ICR1 methylation explain the
difference in IGF2 expression between the two groups of tumors.
Discussion
The role of IGF2 in the progression of adrenocortical
carcinoma (ACC) has been debated for almost two decades. This
question is becoming increasingly important to address, and may
help the design of targeted therapies for this aggressive tumor
which has a very poor prognosis. Two observations implicate
IGF2 in ACC tumorigenesis: (i) the antiproliferative consequences
of the inhibition of IGF2 function in ACC cell lines, and (ii) the
overexpression of IGF2 in ACC.
In the present work, we investigated the role of IGF2 in ACC by
several original approaches including phenotypic comparison
between IGF2-high and IGF2-low ACC carcinoma, transcrip-
tomic analysis, and knock-down of IGF2 in H295R cells with
siRNA.
Logie´ et al. were the first to report that antibodies against IGF2
and IGF1R inhibit the proliferation of H295R cells [16]. More
recently, it has been demonstrated that an anti-IGFR1 monoclo-
nal antibody (IMC-A12) or a tyrosine kinase inhibitor specific for
IGF1R (NVP-AEW541) are able to inhibit the proliferation of
H295R cells both in vitro and in mouse xenografts [18]. This
growth-promoting effect has also been demonstrated in other
adrenocortical tumor cell lines: SW-13 cells do not express high
levels of IGF2 and mouse Y1 cells do not express IGF1R;
however, SW-13 cells proliferate rapidly in the presence of IGF2
[35] and Y1 cells proliferate rapidly when IGF1R is overexpressed
[36]. We used siRNA to inhibit the endogenous production of
IGF2, which demonstrated the important role of IGF2 in
proliferation, cell cycle progression and apoptosis of H295R cells.
These results confirm that IGF2 is an important growth factor at
least in vitro in the adrenocortical cell line H295R.
Mouse models in which IGF2 is specifically overexpressed in the
adrenal cortex have been recently developed [24,25]. In the first of
these models, the overexpression of IGF2 did not initiate adrenal
tumorigenesis. Its overexpression in mice expressing a constitu-
tively active form of beta-catenin in the adrenal cortex resulted in
adrenal hyperplasia, but did not modify tumor phenotype [24]. In
another mouse model of Wnt/beta-catenin pathway activation in
the adrenal cortex, (the adrenocortical APC KO mouse), Heaton
et al. were also unable to identify any effect of IGF2 overexpres-
sion on tumor progression [25]. This may be due to differences
between species; nonetheless, these concordant observations
introduce some doubt on the role of IGF2 in the initiation/
progression of adrenocortical tumorigenesis.
IGF2 is expressed in the normal adrenal cortex and ACA, but
accumulating data demonstrate that IGF2 is the most differentially
expressed gene between malignant and benign adrenocortical
tumors [14,15,19-22,34]. In these studies, the abundance of IGF2
mRNA was 14 to 120-fold higher in ACC than in ACA,
depending on the probe used. Similarly, overproduction of the
IGF2 protein and its various isoforms has been demonstrated (x8
to 80), with a strong correlation between protein and mRNA
abundance [13]. In the present cohort, we found that the
expression of IGF2 was 20-fold higher in ACC than in ACA,
which confirms that IGF2 is the most differentially expressed gene
between malignant and benign tumors [21].
We explored whether this difference in IGF2 expression was
associated with differences in the phenotype or tumor biology
significant impairment of cell growth B: Doxycycline (black square) does not inhibit proliferation in a control clone. C, D: Effect of IGF2 knock-down on
the cell cycle. After 7 days of doxycycline treatment, the cell cycle was analyzed by PI staining and flow cytometry. Cells expressing IGF2 shRNA were
largely arrested in the G1 phase of the cell-cycle and few cells were in S phase (C). Results are presented for clone 1, which showed the most
significant G1 cell cycle arrest. Doxycycline treatment did not affect the cell cycle of a control clone (D). E-H: Apoptosis studied by flow cytometry
after PI (Propidium iodide) and Annexin V staining. E: Example of FACS results for clone 4, showing the apoptotic status of cells according to Annexin
V (X axis) and PI (Y axis) staining. F, G: Study of non-induced apoptosis after prolonged IGF2 knock-down. Ten days after shRNA induction by
doxycycline treatment, cells were stained and analyzed by flow cytometry. Doxycycline treatment did not affect apoptosis of the control clone
without integrated shRNA (G). Both early and late apoptosis were significantly higher in cells expressing IGF2 shRNA than in control cells (F). Results
are presented for clone 4, which showed the most significant difference in apoptosis. H: Study of TNF-alpha-induced apoptosis after the transient
knock-down of IGF2 in H295R cells. Cells were treated with TNF-alpha 48 h after siRNA transfection, and were analyzed by flow cytometry 48 h later.
The number of viable cells was significantly lower in cells transfected with siRNA against IGF2 (black bars), and the percentage of cells in late
apoptosis was significantly higher than in cells transfected with a control siRNA (white bars). Results were analyzed with the Wilcoxon test. *: p,0.05.
***: p,0.001. All the results presented in this figure are representative of at least three independent experiments.
doi:10.1371/journal.pone.0103744.g004
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between the two groups of ACC. The clinical presentation of
IGF2-high and IGF2-low tumors was the same. Therefore, it is not
surprising that the overall and disease free survival did not differ
between patients with IGF2-high and patients with IGF2-low
tumors. This result is in agreement with previous reports
indicating that IGF2 overexpression has no predictive value for
prognosis or metastasis [19]. This inability to distinguish the two
groups of tumors based on clinical characteristics was associated
with similar proliferative histological features as assessed by
comparable median Weiss scores and Ki67 indexes. In addition,
classical molecular markers of adrenocortical carcinoma could not
distinguish between IGF2-high and IGF2-low tumors, and
although there were some differences in the transcriptome profiles
between these two groups of tumors in the supervised analysis,
there was no obvious difference in the unsupervised analysis [21].
Figure 5. Structure and methylation of the 11p15 locus. A. Schematic representation of the 11p15 locus. The 11p15 locus is represented with
the 2 differentially imprinted regions (ICR1 & ICR2). In the maternal allele H19 is expressed but not IGF2 as the consequence of CTCF binding to a
sequence located between the 2 genes and acting as an insulator. Therefore the enhancer (E) can only activate the transcription of the most proximal
gene. The methylation (CH3) of this sequence (paternal allele) prevents the binding of CTCF, allows the expression of IGF2 and represses that of H19.
The methylation (maternal allele) or not (paternal allele) of ICR2 results in the opposite expression of CDKN1C, KCNQ1 and KCNQ10T. Genes with
activation or repression of their expression are indicated in green or red respectively. The most frequent patterns observed in IGF2-high (left) and
IGF2-low (right) ACC are indicated in the lower part of the figure. B: Methylation of the 11p15 imprinting center regions in IGF2-high (n = 15) and
IGF2-low (n = 9) ACC. The percentage of methylation (y-axis) is shown for ICR1 (blue circles) and ICR2 (red squares). Wilcoxon test results (**p,0.01;
NS = not significant) are indicated. Dotted lines connect data from the same tumor, and indicate paternal uniparental disomy (pUPD) when ICR1 is
highly methylated and ICR2 is weakly methylated. This pUPD pattern is present in almost all IGF2-high ACC, whereas it is present in only three out of
nine IGF2-low ACC.
doi:10.1371/journal.pone.0103744.g005
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Altogether, these data indicate that the major difference between
the two groups of tumors is IGF2 expression.
We next analyzed whether IGF2 overexpression was associated
with changes in the expression or activity of members of the IGF
signaling pathway. Several reports have shown differences in the
abundance of IGF1R [19,37-40] IGF2R [41] and IGFBP2
protein but not mRNA [13] between ACC and ACA. In addition,
there are conflicting reports about whether the activity of the Akt/
PI3kinase pathway is higher in malignant tumors than in benign
tumors [18,42]. In the microarray data of our series of 140
Figure 6. Expression of the genes in the 11p15 imprinted region. A: Snapshot heat map of the 11p15 chromosomal region generated from a
previous transcriptomic study (21). Expression levels of imprinted genes IGF2, IGF2AS, H19, CDKN1C, KCNQ1, and KCNQ1OT1 are shown for 47 ACA, six
IGF2-low ACC and 23 IGF2-high ACC. Red: high expression. Green: low expression. B: Boxplots showing expression data for the same genes. Wilcoxon
test results (*p,0.05; **p,0.01; ***p,0.001; NS =not significant) are indicated. Except for IGF2 and IGF2AS, there are no significant differences
between IGF2-high and IGF2-low ACC.
doi:10.1371/journal.pone.0103744.g006
IGF2 in Adrenocortical Carcinoma Growth
PLOS ONE | www.plosone.org 11 August 2014 | Volume 9 | Issue 8 | e103744
adrenocortical tumors, the expression of IGF1R in ACC was
similar to that in ACA (data not shown). The expression of IGF2R
was moderately but significantly higher in ACC than in ACA, in
contrast with the expected LOH of this gene in ACC, which codes
for an inhibitor of proliferation [41]. In addition, these data
confirm IGFBP2 is not differentially expressed between ACA and
ACC, but indicate several significant differences in the expression
of IGFBP, including the higher expression of (IGFBP3) and the
lower expression of (IGFBP5 and 6) in ACC than in ACA.
We also compared the expression and activity of the partners of
the IGF signaling pathway between IGF2-high and IGF2-low
ACC. Surprisingly, none of these genes showed any difference in
expression between the two types of tumor both at the mRNA and
protein levels, except for Erk2. This result contrasts with the
literature, which indicates that IGF1R overexpression is a feature
of many cancers [43] and that MEF cells with LOI at 11p15 (the
classic mechanism for IGF2 overexpression) express more IGF1R
and INSR than cells without LOI [44].
In addition, IGF2 expression did not affect significantly Akt and
Erk phosphorylation, and therefore the activity of the tyrosine
kinase signaling pathways, although the activation of IGF1R/
INSR was significantly higher in IGF2-high ACC than in IGF2-
low ACC. Similarly, the knock-down of IGF2 in H295 cells
inhibited cell proliferation and stimulated apoptosis without any
identifiable change of PI3K/Akt and MAP kinase signaling
pathway activities. This may be due to the transitory nature of
this inhibition, which is rapidly compensated either by IGF1R/
INSR desensitization or by activation of other growth promoting
pathways. The most probable explanation for these discrepancies
is that many other growth factors that signal through tyrosine
kinase receptors are active in ACC. Several other growth factor
receptors (FGFR1, FGFR4 and EGFR) are overexpressed in ACC
[38,45]. The comparison of the transcriptome between IGF2-high
and IGF2-low ACC also showed that the expression of some
growth factors (FGF9, PDGFA) was higher in IGF2-low ACC
than in IGF2-high ACC. Altogether, these data suggest that many
other growth factors or alterations are involved in ACC
progression.
Finally, we explored the molecular mechanism, which may
explain differences in IGF2 expression amongst ACC. The IGF2
gene lies on an imprinted region of chromosome 11p15, which is a
region with a complex epigenetic regulation. The molecular
mechanism of IGF2 overexpression in adrenocortical tumors is
linked with paternal UPD (see the results section for details),
resulting in methylation of ICR1 and demethylation of ICR2
[14,34]. We identified pUPD in most IGF2-high ACC of our
series; these samples showed the expected methylation profiles at
ICR1 and ICR2 (80% of the tumors) and the expression of the five
imprinted genes at this loci differed as expected from their
expression in ACA. This pUPD is considered as an early event in
the tumorigenesis process because it is absent in most adenoma
(90%) and is present in most carcinoma (80 to 90% depending on
the series, 82% in our series). In IGF2-low tumors, we found
similar pUPD and hypomethylation of ICR2 with corresponding
modifications of imprinted gene expression; interestingly however,
most of these tumors also showed low methylation of ICR1
associated with a low expression of IGF2 and a moderate
expression of H19. This additional epigenetic event may explain
the low production of IGF2 in IGF2-low tumors.
In conclusion, most ACC express large amounts of IGF2, which
appears to be a driving force for the progression of tumorigenesis.
This hypothesis is being tested in ongoing trials involving anti-IGF
therapies [46]. IGF2 is not overexpressed in a small subset of
ACC, as a result of epigenetic modifications at the 11p15 locus.
The origin of this subset of tumors is unclear. IGF2-high and
IGF2-low tumors present no major clinical and transcriptomic
differences and both show pUPD, suggesting a shared mechanism
of tumorigenesis. It is not known whether IGF2 overexpression is
absent at the beginning of tumorigenesis or whether it is lost
during the progression of the IGF2-low tumor. However, it is
probable that in this small subset of IGF2-low ACC other growth
factors and signaling pathways compensate for low IGF2
expression, which creates opportunities for the design of other
therapies targeting these factors.
Supporting Information
Figure S1 Cellular models of IGF2 knock-down in
adrenal carcinoma. A: Transient extinction of IGF2 expres-
sion by siRNA in H295R cells. Cells were transfected twice at day
1 and 2 after plating, either with siRNA against IGF2 (black bars)
or with control siRNA (white bars). Levels of IGF2 mRNA were
measured by qRT-PCR at days 2, 3, and 5 after the first
transfection. IGF2 expression was reduced by 85% at days 2 and
3, and 74% at day 5. B: Long-term extinction of IGF2 by shRNA
in H295R cells. Levels of IGF2 mRNA were measured by qRT-
PCR after 2 (d2) or 10 (d10) days after doxycycline treatment
(black bars), and compared with those obtained in the absence of
doxycycline (white bars). Results are presented here for 4 different
clones, with 40 to 75% (d2) or 65 to 90% (d10) reduction of IGF2
expression. PP1A gene is used as a reference in both experiments
and expression ratio between IGF2 and cyclophilin has been
considered as 1 for the control experiment (control siRNA for A
and no doxycyclin for B). Results were analysed using Wilcoxon
test. *: p-value,0.05 Results are representative of at least 3
independent experiments.
(TIF)
Figure S2 Study of IGF2 receptors, Erk, and Akt
activation by western blot after 2, 7, or 10 days of
IGF2 knock-down in stably transfected clones. For each
clone, expression of proteins was normalized to GAPDH
expression, and fixed to 1 in the absence of doxycycline (white
bars). Means and standard deviations of these ratios for 3 different
clones after doxycycline treatment are indicated (black bars). A, D,
F: Activated proteins as determined by their level of phosphor-
ylation. B, C, E,G: Total proteins A, B, C: IGF2 receptors. D,E:
Erk. F,G: Akt. Results were analysed using Wilcoxon test. *: p-
value,0.05.
(TIF)
Table S1 Primers for quantitative RT-PCR and se-
quencing. Sequences, annealing temperatures, and PCR effi-
ciencies are presented for each quantitative RT-PCR primer set.
(XLS)
Table S2 Western blot antibodies. Reference, supplier and
dilution are indicated for the different antibodies used in this study.
(XLS)
Table S3 Results of transcriptomic studies on tumors.
ACC-genes worksheet bar: from the transcriptome study already
published (21), genes with significantly different expression
between IGF2-low and IGF2-high ACC were determined using
Limma T-Test. Green: genes significantly more expressed in
IGF2-high ACC. Red: genes less expressed in IGF2-high ACC. A
list of the genes without significantly different expression is
available upon request. GM: Geometric Mean (log2). FC: Fold
Change (log2). ACC-pathways worksheet bar: Pathways with
enrichment in IGF2-high or IGF2-low ACC. Green: genes
significantly more expressed in IGF2-high ACC. Red: genes less
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expressed in IGF2-high ACC. In the ‘‘Summary’’ column,
enrichment of the pathway with genes up or down regulated in
IGF2-low ACC is shown. A list of the pathways without
enrichment in IGF-high or IGF2-low ACC is available upon
request.
(XLS)
Table S4 Transcriptomic studies on cellular models.
Cellular models-genes worksheet bar: ratios of gene expression
with and without IGF2 knock-down in different experiments with
cellular models. Log2r:Log2 of the ratio. si.serum and si.noserum:
experiments of 5-day IGF2 extinction with IGF2 siRNA with
complete or depleted culture medium, respectively. Experiments
with 2 (d2) or 10 (d10) days of IGF2 knock-down by shRNA (sh) in
3 independent clones (.1, .2, .3) are also reported. Finally, mean of
the ratios (log2r.mean) and p-values of paired t-test in the 8
independent experiments are highlighted in yellow. Only genes
with significant p-values are indicated. A list of the genes without
significantly different expression is available upon request. Cellular
models-pathways worksheet bar: pathways with enrichment in
cells with or without IGF2knock-down. Up genes (in red): genes
up-regulated when IGF2 is knocked-down. Down genes (in green):
genes down-regulated when IGF2 is knocked-down. In the
‘‘Summary’’ column, the enrichment in up or down-regulated
genes of the pathway in cells without IGF2 extinction (IGF2-high
ACC cells) is specified. A list of the pathways without enrichment
in IGF2-high or IGF2-low cells is available upon request.
(XLS)
Table S5 IGF2 targets in adrenocortical carcinoma and
H295R cells. This table shows the genes regulated in the same
way (up or down-regulated) in tumors and cellular models.
log2(ratio IGF2-/IGF2+): mean of log2 ratios of the 8 experiments
in cellular models (see table S3). PairedTTest.pvalue: p-value of
the paired t-test performed on the 8 independent experiments in
cellular models (see table S3). moderate T-test p.values: p-values of
the Limma test performed between IGF2_high and IGF2-low
carcinoma. log2(Fold change IGF2-/IGF2+): log 2 of fold change,
IGF2-low carcinoma over IGF2-high carcinoma. In red: genes
positively correlated to IGF2. In green: genes negatively correlated
to IGF2.
(XLS)
Table S6 Quantitative expression of IGF2 signalling
pathway, cell cycle and growth factor genes in IGF2-low
and IGF2-high adrenal carcinoma. Results for different
genes of the IGF2 pathway are presented, as determined by qRT-
PCR (mRNA level) or western blot (protein level). Medians for
IGF2-high and IGF2-low carcinoma, as fold change and p-value
between the 2 groups are indicated. In bold: significant results.
(XLS)
Acknowledgments
The authors would like to thank the Comete network and P. F Plouin for
the organization and collection of adrenal tumors over the past 20 years.
They would like also to thank the genomic and cytometry platforms of
Cochin Institute, for transcriptomic and FACS experiments, respectively
and also Karine Perlemoine for technical assistance.
Author Contributions
Conceived and designed the experiments: MGB EC YLB JB GA XB EB.
Performed the experiments: MGB BR CC IF OB VS JG FT MRR FRC.
Analyzed the data: MGB AdR BR FT OB GA YLB JB EC. Contributed
reagents/materials/analysis tools: AAG EB JB. Wrote the paper: MGB
AdR XB GA BR YLB JB EC.
References
1. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors:
implications for drug design. Nat Rev Drug Discov 1: 769–783.
2. Harris LK, Westwood M (2012) Biology and significance of signalling pathways
activated by IGF-II. Growth Factors 30: 1–12.
3. Gourmelen M, Perin L, Le Bouc Y (1994) IGFs and their binding proteins. Nucl
Med Biol 21: 297–302.
4. Callan AC, Milne E (2009) Involvement of the IGF system in fetal growth and
childhood cancer: an overview of potential mechanisms. Cancer Causes Control
20: 1783–1798.
5. Zhan S, Shapiro DN, Helman LJ (1994) Activation of an imprinted allele of the
insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin
Invest 94: 445–448.
6. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, et al. (1989)
Autonomous growth of a human neuroblastoma cell line is mediated by insulin-
like growth factor II. J Clin Invest 84: 829–839.
7. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, et al. (1988)
Differential expression of insulin-like growth factor II mRNA in human primary
liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48: 6844–
6849.
8. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, et al. (1986)
Enhanced levels of insulin-like growth factor messenger RNA in human colon
carcinomas and liposarcomas. Cancer Res 46: 6169–6173.
9. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, et al.
(1994) Rearrangements at the 11p15 locus and overexpression of insulin-like
growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol
Metab 78: 1444–1453.
10. Ribeiro TC, Latronico AC (2012) Insulin-like growth factor system on
adrenocortical tumorigenesis. Mol Cell Endocrinol 351: 96–100.
11. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, et al. (1990) Clinical
features of adrenocortical carcinoma, prognostic factors, and the effect of
mitotane therapy. N Engl J Med 322: 1195–1201.
12. Else T, Kim A, Sabolch A, Raymond V, Kandathil A, et al. (2013)
Adrenocortical carcinoma. Endocrine reviews: er20131029.
13. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y (1998) Increased levels of
insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated
with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab
83: 1713–1720.
14. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, et al. (2001) Molecular
markers and long-term recurrences in a large cohort of patients with sporadic
adrenocortical tumors. Cancer Res 61: 6762–6767.
15. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, et al. (1997)
Structural and functional abnormalities at 11p15 are associated with the
malignant phenotype in sporadic adrenocortical tumors: study on a series of 82
tumors. J Clin Endocrinol Metab 82: 2559–2565.
16. Logie A, Boulle N, Gaston V, Perin L, Boudou P, et al. (1999) Autocrine role of
IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell
line. J Mol Endocrinol 23: 23–32.
17. Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, et al. (2008) Mitotane
increases the radiotherapy inhibitory effect and induces G2-arrest in combined
treatment on both H295R and SW13 adrenocortical cell lines. Endocrine-
related cancer 15: 623–634.
18. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, et al. (2009)
Preclinical targeting of the type I insulin-like growth factor receptor in
adrenocortical carcinoma. J Clin Endocrinol Metab 94: 204–212.
19. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, et al. (2008)
Expression of insulin-like growth factor-II and its receptor in pediatric and adult
adrenocortical tumors. J Clin Endocrinol Metab 93: 3524–3531.
20. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, et al. (2005)
Gene expression profiling of human adrenocortical tumors using complementary
deoxyribonucleic Acid microarrays identifies several candidate genes as markers
of malignancy. J Clin Endocrinol Metab 90: 1819–1829.
21. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, et al. (2009) Gene
expression profiling reveals a new classification of adrenocortical tumors and
identifies molecular predictors of malignancy and survival. J Clin Oncol 27:
1108–1115.
22. Giordano TJ (2003) Gene expression profiling of endocrine tumors using DNA
microarrays: progress and promise. Endocr Pathol 14: 107–116.
23. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, et al. (2005)
Expression profiling of adrenocortical neoplasms suggests a molecular signature
of malignancy. Surgery 138: 1087–1094.
24. Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, et al. (2012) Analysis
of the role of Igf2 in adrenal tumour development in transgenic mouse models.
PLoS One 7: e44171.
25. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, et al. (2012)
Progression to adrenocortical tumorigenesis in mice and humans through
insulin-like growth factor 2 and beta-catenin. Am J Pathol 181: 1017–1033.
IGF2 in Adrenocortical Carcinoma Growth
PLOS ONE | www.plosone.org 13 August 2014 | Volume 9 | Issue 8 | e103744
26. Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic
significance in adrenocortical carcinoma. Am J Surg Pathol 13: 202–206.
27. Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, et al. (2007) Somatic TP53
mutations are relatively rare among adrenocortical cancers with the frequent
17p13 loss of heterozygosity. Clin Cancer Res 13: 844–850.
28. Groussin L, Massias JF, Bertagna X, Bertherat J (2000) Loss of expression of the
ubiquitous transcription factor cAMP response element-binding protein (CREB)
and compensatory overexpression of the activator CREMtau in the human
adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 85: 345–354.
29. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, et al. (2007)
Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation
and cancer. Mol Endocrinol 21: 2968–2987.
30. Ragazzon B, Lefrancois-Martinez AM, Val P, Sahut-Barnola I, Tournaire C, et
al. (2006) Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio
influence steroidogenic genes expression in a novel model of glucocorticoid-
producing adrenocortical cell lines derived from targeted tumorigenesis.
Endocrinology 147: 1805–1818.
31. Azzi S, Rossignol S, Steunou V, Sas T, Thibaud N, et al. (2009) Multilocus
methylation analysis in a large cohort of 11p15-related foetal growth disorders
(Russell Silver and Beckwith Wiedemann syndromes) reveals simultaneous loss of
methylation at paternal and maternal imprinted loci. Human molecular genetics
18: 4724–4733.
32. Azzi S, Steunou V, Rousseau A, Rossignol S, Thibaud N, et al. (2011) Allele-
specific methylated multiplex real-time quantitative PCR (ASMM RTQ-PCR),
a powerful method for diagnosing loss of imprinting of the 11p15 region in
Russell Silver and Beckwith Wiedemann syndromes. Human mutation 32: 249–
258.
33. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, et al. (2009)
Limited prognostic value of the 2004 International Union Against Cancer
staging classification for adrenocortical carcinoma: proposal for a Revised TNM
Classification. Cancer 115: 243–250.
34. Gicquel C, Le Bouc Y (1997) Molecular markers for malignancy in
adrenocortical tumors. Horm Res 47: 269–272.
35. Shen W, Xian J, Hu WL, Liu J, Liu J (2007) [Effect of insulin-like growth factor
and its receptor-I antibody on growth of human adrenocortical carcinoma SW-
13 cell lines in vitro]. Nan fang yi ke da xue xue bao = Journal of Southern
Medical University 27: 88–91.
36. Weber MM, Fottner C, Wolf E (2000) The role of the insulin-like growth factor
system in adrenocortical tumourigenesis. European journal of clinical investi-
gation 30 Suppl 3: 69–75.
37. Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovsky MA, et al.
(1999) Comparative genomic hybridization analysis of adrenocortical tumors of
childhood. J Clin Endocrinol Metab 84: 1116–1121.
38. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, et al.
(2007) Gene expression profiling of childhood adrenocortical tumors. Cancer
Res 67: 600–608.
39. Kamio T, Shigematsu K, Kawai K, Tsuchiyama H (1991) Immunoreactivity
and receptor expression of insulinlike growth factor I and insulin in human
adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138:
83–91.
40. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D (1997) Insulin-like
growth factor receptors in normal and tumorous adult human adrenocortical
glands. Eur J Endocrinol 136: 296–303.
41. Leboulleux S, Gaston V, Boulle N, Le Bouc Y, Gicquel C (2001) Loss of
heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor
locus: a frequent but late event in adrenocortical tumorigenesis. Eur J Endo-
crinol 144: 163–168.
42. Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, et al. (2005) AKT is
highly phosphorylated in pheochromocytomas but not in benign adrenocortical
tumors. J Clin Endocrinol Metab 90: 4366–4370.
43. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia.
Nat Rev Cancer 8: 915–928.
44. Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, et al. (2007) Enhanced
sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell
proliferation and tumor risk. Proc Natl Acad Sci U S A 104: 20926–20931.
45. Edgren M, Eriksson B, Wilander E, Westlin JE, Nilsson S, et al. (1997) Biological
characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67
and PCNA in 17 adrenocortical carcinomas. Anticancer Res 17: 1303–1309.
46. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, et al. (2010) Safety,
tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody
figitumumab in patients with refractory adrenocortical carcinoma. Cancer
Chemother Pharmacol 65: 765–773.
IGF2 in Adrenocortical Carcinoma Growth
PLOS ONE | www.plosone.org 14 August 2014 | Volume 9 | Issue 8 | e103744
